CLINICAL OUTCOMES AND MOLECULAR CHARACTERIZATION FROM a PHASE II STUDY OF COPANLISIB IN PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) - Lenz, G.; Hawkes, E.; Verhoef, G.; Haioun, C.; Lim, S.; Heo, D.; Ardeshna, K.; Chong, G.; Christensen, J.H.; Shi, V.; Lippert, S.; Hiemeyer, F.; et al.